South Dakota Investment Council lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,270,583 shares of the biopharmaceutical company’s stock after purchasing an additional 42,006 shares during the period. Pfizer comprises approximately 0.8% of South Dakota Investment Council’s investment portfolio, making the stock its 17th largest holding. South Dakota Investment Council’s holdings in Pfizer were worth $46,033,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in Pfizer by 2.2% in the 1st quarter. BlackRock Inc. now owns 405,733,970 shares of the biopharmaceutical company’s stock worth $14,699,742,000 after acquiring an additional 8,760,458 shares during the last quarter. Geode Capital Management LLC increased its holdings in Pfizer by 4.1% in the 1st quarter. Geode Capital Management LLC now owns 94,148,117 shares of the biopharmaceutical company’s stock worth $3,402,339,000 after acquiring an additional 3,699,308 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Pfizer by 12.1% in the 4th quarter. Bank of New York Mellon Corp now owns 64,756,839 shares of the biopharmaceutical company’s stock worth $2,383,700,000 after acquiring an additional 6,965,496 shares during the last quarter. Norges Bank purchased a new stake in Pfizer in the 4th quarter worth about $2,219,532,000. Finally, Morgan Stanley increased its holdings in Pfizer by 16.4% in the 4th quarter. Morgan Stanley now owns 53,610,111 shares of the biopharmaceutical company’s stock worth $1,973,389,000 after acquiring an additional 7,540,245 shares during the last quarter. Institutional investors own 64.22% of the company’s stock.
NYSE:PFE traded up $0.07 during mid-day trading on Thursday, reaching $39.12. The stock had a trading volume of 164,561 shares, compared to its average volume of 30,052,848. The company has a 50 day moving average price of $39.29. The company has a market capitalization of $218.98 billion, a PE ratio of 19.92, a P/E/G ratio of 1.43 and a beta of 0.73. Pfizer Inc. has a one year low of $31.61 and a one year high of $43.08. The company has a quick ratio of 1.16, a current ratio of 1.48 and a debt-to-equity ratio of 0.51.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 7th. Shareholders of record on Friday, July 30th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 3.99%. Pfizer’s payout ratio is currently 70.27%.
In other Pfizer news, SVP Jennifer B. Damico sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 5th. The stock was sold at an average price of $40.82, for a total value of $102,050.00. Following the completion of the sale, the senior vice president now owns 13,748 shares in the company, valued at $561,193.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.05% of the company’s stock.
A number of research analysts have weighed in on the company. The Goldman Sachs Group set a $45.00 target price on Pfizer and gave the company a “neutral” rating in a report on Monday, May 24th. Royal Bank of Canada lifted their target price on Pfizer from $43.00 to $44.00 and gave the company a “sector perform” rating in a report on Thursday, June 17th. JPMorgan Chase & Co. set a $40.00 target price on Pfizer and gave the company a “neutral” rating in a report on Monday, May 24th. Mizuho reaffirmed a “neutral” rating and set a $42.00 target price on shares of Pfizer in a report on Wednesday, May 12th. Finally, TheStreet raised Pfizer from a “c+” rating to a “b-” rating in a report on Monday, May 3rd. Twelve equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $40.20.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.
Further Reading: Diversification in Investing
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.